We’re proud to share that the FDA has granted Rare Pediatric Disease Designation to PBGENE-DMD, our ARCUS gene editing therapy for Duchenne muscular dystrophy. Cindy Atwell, Chief Development & Business Officer, shares what this milestone means for our team and the DMD

We're back at the Jefferies Global Healthcare Conference!. Michael Amoroso, Chief Executive Officer, and Cassie Gorsuch, PhD, Chief Scientific Officer, joined Maury Raycroft for a fireside chat. Want to listen? #GeneEditing #DMD #PrecisionBioSciences

☀️ Summer is starting, but the Precision team isn't slowing down!. Gary Owens, Program Leader for PBGENE-DMD at Precision BioSciences, recently attended and presented at the CureDuchenne FUTURES National Conference. With compelling preclinical evidence, PBGENE-DMD, Precision's

📸 On the ground at #ASGCT2025 — the Precision BioSciences team proudly presented preclinical data for PBGENE-DMD, our first-in-class in vivo gene editing therapy for the majority of Duchenne muscular dystrophy (DMD) patients. 🧬 Using our proprietary ARCUS platform, PBGENE-DMD

Precision BioSciences announced its Q1 2025 earnings and provided a business update!. 🧬 PBGENE-HBV:.✔️ Fast Track designation.✔️ Encouraging safety + early efficacy data.✔️ Now cleared for trials in 5 countries.✔️ Clinical data presented at EASL - safe after two doses. 💪

Last week, Michael Amoroso, Chief Executive Officer, and Cassie Gorsuch, PhD, Chief Scientific Officer, spoke in a fireside chat at the Citizens Life Sciences Conference in New York. Want to hear what they had to say? . Visit #GeneEditing #Biotech #DTIL

Precision BioSciences hit another major milestone. ✅. PBGENE-HBV, our wholly owned in vivo gene editing program for chronic hepatitis B, has received Fast Track designation from the FDA—unlocking new potential for accelerated development and long-term value!. 🌍 Global Phase 1

The Precision team sat down with Soumit Roy, PhD, at the Jones Healthcare & Technology Innovation Conference!. Cassie Gorsuch, PhD, CSO, and Alex Kelly, CFO, spoke about Editing Tomorrow, Today. For the full convo, #GeneEditing #Biotech #DTIL

ARCUS understands the importance of simplicity!. ➡️ Only single component editor that recognizes and cuts DNA.➡️ Single component streamlines delivery and results in the highest efficiency.➡️ Single component editor requires a lower dose of delivery vehicle. For the full picture,

Does size matter? 📏. For ARCUS it does. ➡️ Smallest gene editor (~1500 bp).➡️ Enables delivery of MORE payload, which then enables sophisticated edits.➡️ Delivery, both non-viral and viral, to diverse tissues in the body. ARCUS—designed by nature for a multitude of applications

ARCUS is a proprietary genome editing technology discovered by scientists at Precision BioSciences. The unique advantages of ARCUS relate to the type of cut, small size, and simplicity. Let's talk about: The Cut ✂️. ➡️ 3 Prime Overhang Cut.➡️ Homology-Directed Repair (HDR).➡️

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update!. ✅ Announced first in vivo clinical validation for ARCUS gene editing across two distinct programs including wholly owned PBGENE-HBV and partnered program ECUR-506

Last week, Dr. Cassie Gorsuch, PhD, Chief Scientific Officer, presented preclinical efficacy and durability data on PBGENE-DMD for the treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference. "While there has

🇺🇸 What does the recent U.S. FDA Investigational New Drug (IND) clearance for PBGENE-HBV mean for clinicians?. 🧬 What stands out about the early clinical data generated at the first dose level of PBGENE-HBV?. 💡 What are the biggest challenges that Hepatitis B patients face

At Precision, we're Dedicated to Improving Life, or #DTIL. Sinu Bhandaru, our Vice President of Operations and IT, shares a message of optimism: “We’re getting closer to life-changing treatments, don’t lose hope.”. #GeneEditing #Biotech $DTIL

Today is #RareDiseaseDay 💜. The Precision team is driven to make a difference and stand with the rare disease community, championing innovation and hope. Together, we can change lives. #ShowYourStripes #DTIL

Initial PBGENE-HBV results are in!. Today, Precision BioSciences announced initial safety and antiviral activity of PBGENE-HBV in the ELIMINATE-B Phase 1 dose-finding study for chronic Hepatitis B. This marks the SECOND clinical validation for ARCUS in vivo gene editing in 2025.

Guggenheim hosted the Precision team for a Fireside Chat at its Securities SMID Cap Biotech Conference!. Webcast link: *A webcast of the presentation will also be accessible on Precision’s website, $DTIL